Mer­ck calls ACIP's pneu­mo­coc­cal rec­om­men­da­tion a 'missed op­por­tu­ni­ty,' ad­vo­cates for ex­pand­ing age group

The CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices (ACIP) has rec­om­mend­ed Mer­ck’s re­cent­ly ap­proved 21-va­lent pneu­mo­coc­cal vac­cine Cap­vax­ive for adults 65 years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.